The FDA recently granted accelerated approval for pembrolizumab in combination with pemetrexed and carboplatin for the treatment of patients with previously untreated metastatic non-small cell lung cancer (non-squamous). This is the first approval to combine immunotherapy with chemotherapy in lung cancer. The trial compared standard chemotherapy to pembrolizumab along with standard chemotherapy in patients that… Read more »
